Journals / The European Research Journal / 2016 / Cilt: 2 - Sayı: 1

Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin's lymphoma

Pages
52–61
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore,it is important for medical centres to evaluate their treatment outcomes, and prognostic factors affecting theirsurvival rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Non-Hodgkin Lymphomas (NHLs) are tumours of the lymphoid system which originate fromlymph nodes or extranodal lymphatic tissue.
📊
Key Findings & Data:The objective of our study is to investigate clinical characteristics, treatments applied, and theiroutcomes, survival rates, and prognostic factors which may be effective on survival.
💡
Conclusion & Impact:Therefore,it is important for medical centres to evaluate their treatment outcomes, and prognostic factors affecting theirsurvival rates.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives. Non-Hodgkin Lymphomas (NHLs) are tumours of the lymphoid system which originate fromlymph nodes or extranodal lymphatic tissue. Since they represent a heterogeneous group of diseases, it is veryimportant to determine prognostic factors apart from staging and identification of the patients with poorprognosis. The objective of our study is to investigate clinical characteristics, treatments applied, and theiroutcomes, survival rates, and prognostic factors which may be effective on survival. Methods. Clinicalcharacteristics, treatments applied, and their outcomes, survivals, and prognostic factors which may be effectiveon the survival in 230 patients who were diagnosed as NHL, and consulted to our center between the years2002, and 2015 were retrospectively evaluated. Results. Median age of our patients (male, 54.8 %, and female,45.2 %) was 57 years. The most frequently seen histopathological subtype was diffuse large ? cell lymphoma.We have seen that IPI score, ? symptom, levels of LDH, albumin, ?2 microglobulin, and lymphocyte countsare significant prognostic factors. Stomach was the most frequently involved extranodal organ. Advanced stage,higher IPI score, extranodal organ involvement were found to be correlated with shorter survival times.Conclusion. Everyday developments occur in the diagnosis, classification, and treatment of NHL. Therefore,it is important for medical centres to evaluate their treatment outcomes, and prognostic factors affecting theirsurvival rates.

🔖

Cite This Article

TABAKAN, F., NAYIR, E., ARICAN, A. (2016). Clinical and pathological evaluation of histopathological subtypes in patients with non-Hodgkin's lymphoma. The European Research Journal, Cilt: 2 - Sayı: 1, 52–61. https://ajindex.com/articles/361186

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Jamil MO, Mehta A. Diffuse large B-cell lymphoma: prognostic markers and their impact on therapy. Expert Rev Hematol. 2016 Feb;19:1-7.
  2. Isikdogan A, Ayyildiz O, Buyukcelik A, Arslan A, Tiftik N, Buyukbayram H, et al. Non-Hodgkin's lymphoma in southeast Turkey: clinicopathologic features of 490 cases. Ann Hematol. 2004 May;83(5):265-9. Swerdlow AJ. Epidemiology of Hodgkin's disease and non- Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S3-12. Ruacan S. THD, WHO classification overview epidemiology and Turkey. Clinician pathologists common lymphoma course 2004;March:14-7. Kuzu I. Recent developments in non-Hodgkin's lymphoma classification. Hematoloji-Onkoloji. 2000;2:256-67. Disel U. Epidemiology of the lymphoma and staging. Turkiye Klinikleri J Med Oncol-Special Topics. 2009;2(2):17-24. American Cancer Society. Cancer facts and figures. 2016. Available from: URL: www.cancer.org. 7 February 2016.
  3. Lee SS, Cho KJ, Kim CW, Kang YK. Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the Revised European-American Classification of lymphoid neoplasms. Histopathology. 1999 Oct;35(4):345-54.
  4. Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, et al. The rise in incidence of lymphomas in Europe 1985-1992. Eu J Cancer. 1999 Apr;35(4):627-33.
  5. Mitterlechner T, Fiegl M, Muhlbock H, Oberaigner W, Dirnhofer S, Tzankov A. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol. 2006 Jan;59(1):48-55.
  6. Economopoulos T, Papageorgiou S, Dimopoulos MA, Pavlidis N, Tsatalas C, Symeonidis A, et al. Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. Acta Haematol. 2005;113(2):97-103.
  7. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non- Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997 Sep 17;72(6):923-30.
  8. Alici S, Bavbek SE, Kaytan E, Basaran M, Eralp Y, Onat H. Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: Treatment, outcome, and prognostic factors. Am J Clin Oncol. 2002 Oct;25(5):502-8.
  9. Ramesh B, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S, et al. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India Indian J Med Paediatr Oncol. 2013 Oct- Dec;34(4): 299-304.
  10. Frederiksen BL, Brown Pde N, Dalton SO, Steding-Jessen M, Osler M. Socioeconomic inequalities i